Abstract
Erectile dysfunction (ED) affects more than 54% of Czech men aged 35-65 years. The vast majority of ED cases are secondary to vasculogenic disorders ,including diabetes, and previous radical prostatectomy and neuroloical conditions.
The ideal treatment od ED should be easy to asminister, noc invasive, painless and highly efficacious, with minimal side effects. The first-line treatment for males with ED concsists of oral phosphodiesterase type 5 (PDE5) inhibitor therapy.
Additional shortcomings of the current oral PDE5 inhibitors also include occassional ineffectiveness and limited spontaneity. Avanafil, is highly potent PDE5 inhibior and highly selective for PDE5.
Phase III clinical trials suggests that avanafil is an effective and well tolerated therapy for ED of broad-spectrum etiology nad severity.The improvement in sexual function and tolerability coupled with rapid onset of action and durability of effect, make avanafil a viable tool for on demand treatmen of ED.